Patent SG-11201903835W-A (SG)
Title: Antibodies directed against programmed death- 1 (pd-1)
Inventor: KING DAVID J
IPC: A61K39/395
Filed: 2017-11-01
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#1110111101110101011111 vu 1101 0 0111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/085468 Al 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: A61K 39/395 (2006.01) Cl 2N 15/13 (2006.01) Published: C07K 16/28 (2006.01) — with international search report (Art 2 1 (3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US2017/059618 amendments (Rule 48.2(h)) (22) International Filing Date: 01 November 2017 (01.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,128 01 November 2016 (01.11.2016) US 62/427,777 29 November 2016 (29.11.2016) US (71) Applicants: ANAPTYSBIO, INC. [US/US]; 10421 Pacif- ic Center Court, Suite 200, San Diego, California 92121 (US). TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, Massachusetts 02451 (US). (72) Inventors: KING, David J.; 310 Cole Ranch Road, Encini- _ tas, California 92024 (US). KEHRY, Marilyn; 10440 Rock Creek Drive, San Diego, California 92131 (US). HUANG, Baochuan; c/o Tesaro, Inc., 1000 Winter Street North, Suite = 3300, Waltham, Massachusetts 02451 (US). = Agent: ESPINO, Christine, G. et al.; Proskauer Rose = (74) _ LLP, One International Place, Boston, Massachusetts 02110 — = (US). Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, — AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, — MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — 1-1 GC MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). , tD iv 1 1 in ot (54) Title: ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH- 1 (PD-1) ---- (57) : The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin GC heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related 0 nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive N to PD-1 inhibition, such as cancer or an infectious disease. C